Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Costs of dyslipidemiaHanna Zowall, Steven A GroverHypertension (Dallas, Tex. : 1979)|November 17, 2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?Steven A Grover, Louis Coupal, Hanna ZowallArchives of Internal Medicine|February 13, 2003
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?Steven A Grover, Vivian Ho, Frédéric Lavoie, et al.The Canadian Journal of Cardiology|July 9, 2005
Cost-effectiveness of lipid-lowering treatment according to lipid levelLouise Pilote, Vivian Ho, Frédéric Lavoie, et al.The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.Circulation|June 6, 2007
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF studyGordon W Moe, Jonathan Howlett, James L Januzzi, et al.The Canadian Journal of Cardiology|February 25, 2006
PROVE-IT proves that lower is better: a contrary viewSteven A GroverThe Canadian Journal of Urology|June 1, 1997
Economics of prostate cancer: a computer modelSteven A. GroverThe Canadian Journal of Cardiology|June 21, 2011
The challenges and benefits of cardiovascular risk assessment in clinical practiceSteven A Grover, Ilka LowensteynEpidemiology (Cambridge, Mass.)|July 16, 2003
Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterolSteven A Grover, Marc Dorais, Louis CoupalPageof 4